gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · OGNHealthcarePharmaceuticals

Organon & Co. (OGN)

$13.83−0.14%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$13.85▲ 106.41% in range
Nov 3, 2025Low $5.70 · High $13.85Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Organon & closed at $13.83 on Nov 4, down 0.14%, 0.1% below its 52-week closing high. Volume of 2.6M shares was 1.14× its 20-day average (close to normal).

Split-adjusted performance: +0.7% over one month, +3.1% over six months, +106.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.57B, down 1.7% from a year earlier, with a net margin of 10.4%.

Short interest was 18.8M shares at the Oct 15 settlement (7.2% of float, 8.6 days to cover).

Market cap$3.63B262.6M shares
Revenue · quarter$1.57B−1.7% YoY
Diluted EPS$0.60−1.6% YoY
P/E · TTM17.1×P/S 0.6×
Net margin10.4%Gross 55.2%
Dividend yield0.58%$0.02 last paid
52-week range5.70 – 13.85−0.1% from high
Volume2.6M1.14× 20-day avg
Volatility · 60d2.9%Annualised
Short % of float7.2%8.6 days to cover
Net cash-$7.10BCash $1.46B
Next earnings—Not scheduled
Split-adjusted performance
1W +0.4%1M +0.7%3M +2.1%6M +3.1%YTD +92.9%1Y +106.1%3Y −7.4%5Y −61.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum74
Revenue growth39
Net margin80
Value (low P/E)47
Size87

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short18.8M−0.8% vs prior
Days to cover8.6Settled Oct 15
% of float7.2%
Short vol. 10d45.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
OGNOrganon &$13.83−0.14%+3.1%−1.7%10.4%17.1$3.63B
AMLXAmylyx Pharmaceuticals$29.40+0.68%+83.1%———$3.69BCompare
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare
VKTXViking Therapeutics$27.97+7.21%−13.4%———$3.57BCompare
ACADAcadia Pharmaceuticals$21.47+4.38%0.0%+16.4%10.2%9.7$3.70BCompare
PBLSParabilis Medicines$30.36+3.79%——−45239.9%—$3.75BCompare
XENEXenon Pharmaceuticals$39.19+2.51%−33.1%———$3.80BCompare
DYNDyne Therapeutics$18.54+2.71%−1.6%———$3.46BCompare
ELVNEnliven Therapeutics$47.25+5.40%+14.7%———$3.46BCompare

News about Organon &

All news →
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research · Oct 26, 2026NeutralInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowZacks Investment Research · Oct 14, 2026NeutralHere is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockZacks Investment Research · Oct 2, 2026NeutralHalper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Jun 17, 2026▼ NegativeHalper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Jun 10, 2026▼ Negative

Quick answers

What does Organon & do?
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim.
What is OGN's market cap?
$3.63B, based on the Nov 4 close of $13.83.
What is OGN's P/E ratio?
17.1× trailing-twelve-month earnings of $213M.
Does Organon & pay a dividend?
Yes. The latest regular dividend was $0.02 per share (ex-date Aug 14), an annualised yield of 0.58%.
How much of OGN is sold short?
18.8M shares, 7.2% of float, as of Oct 15, 2026.
What sector is OGN in?
Healthcare, in the Pharmaceuticals industry.

About Organon &

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

HQ: Jersey City, NJ10,000 employeesListed May 14, 2021organon.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology